Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 46309
IPSCIO Record ID: 190857
IPSCIO Record ID: 266238
IPSCIO Record ID: 372435
Licensor grants a non-exclusive license to use the Licensor Trademarks in connection with the Development and Commercialization of the Products.
Compound means xx-011, its derivatives and variants, including molecules that bind both Product Targets and are specifically claimed in Patents that specifically claim the amino acid sequence of xx-011; and any other DART derived from the DART Platform that binds both Product Targets.
DART means a dual affinity re-targeting molecule consisting of two binding arms, whereby the first arm binds a specificity conferred by an antibody variable region and the second arm binds a specificity conferred by a different antibody variable region.
DART Platform means Licensors proprietary platform for generating DARTs.
Indication means a discrete clinically recognized form of a disease, including DLBCL, chronic lymphocytic leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and follicular lymphoma.
Licensor Trademarks means the trademark DART, trademarks which incorporate the acronym DART, and related logos.
xx-011 is a humanized CD19 x CD3 bispecific DART protein.
Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations, including any method of delivery, containing a Compound alone or in combination with other active pharmaceutical ingredients, other than any active pharmaceutical ingredient that is owned or controlled by Licensor, including any Combination Product.
The patents include
— Covalent Diabodies And Uses Thereof;
— Covalent Diabodies And Uses;
— Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life;
— CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3; and,
— Bi-Specific Diabodies That Are Capable Of Binding CD19 And CD3 And Uses Thereof.
B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Prognosis and treatment depend on type and stage of the cancer.
The Field means all uses, including the diagnosis, treatment or prevention of any disease in humans. This agreement specifically discusses the development of xx-011 for Multiple 8-Cell Malignancies.
IPSCIO Record ID: 323411
Granulomatosis with polyangiitis is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. Formerly called Wegener's granulomatosis, this condition is one of a group of blood vessel disorders called vasculitis. It slows blood flow to some of your organs.
IPSCIO Record ID: 3285
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy
IPSCIO Record ID: 280934
Licensor grants the Licensee of Bermuda an exclusive right and license in the Territory, with the right to sublicense, to Develop, make, have made, package and have packaged, use, promote, market, offer for sale, sell and import Licensed Products in the Field, under the Licensor Patents, Licensor Know-How and the Trademark.
Licensor grants during the Term of this Agreement a limited non-exclusive right to use the Licensor Logo on Promotional Literature in the Field in the Territory.
Licensed Products means all pharmaceutical preparations in all dosage strengths, formulations and methods of administration that contain the Compound as its active ingredient, alone or in combination with another active ingredient.
Trademark means the trademark Fodosine or such other trademark approved by the JDC for use in connection with the Licensed Products, but excluding the Secondary Marks.
B-cell Acute Lymphoblastic Leukemia/lymphoma or B-ALL means a disease in which certain cells of the B lymphocytes or B-cells are malignant, and have populated the bone marrow.
B-CLL means B-type chronic lymphocytic leukemia.
B-NHL means a Non-Hodgkinâ€™s lymphoma in which the malignant cells have characteristics predominantly of the B lineage.
Fodosineâ„¢ is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in a number of clinical trials including a Phase IIa clinical trial in patients with T-cell leukemia.
IPSCIO Record ID: 360156
Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, and lymphoma (Hodgkin's and non-Hodgkin's (NHL)).
IPSCIO Record ID: 275366
The product, Ofatumumab, is being commercialized by Licensee.
Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).
IPSCIO Record ID: 4361
The Intellectual Property relates to treatments with opioid antagonists such as naltrexone and et-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkinâ€™s lymphoma, and non-Hodgkinâ€™s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).
U.S. Patent Number 6,586,443
U.S. Patent Number 6,384,044
U.S. Patent Number 6,288,074
U.S. Patent Number 5,356,900
U.S. Patent Number 5,013,739
U.S. Patent Number 4,888,346
In clinical trials, MENK has been shown to reduce early AIDS and AIDS Related Complex, a condition also known as pre-AIDS which include symptoms such as fever, diarrhea, weight loss, swollen lymph nodes and herpes.
IPSCIO Record ID: 25786
SDX-102 is an intravenously administered small molecule which laboratory studies have shown kills tumors which cannot produce an important metabolic enzyme. Safety and tolerability data on SDX-102 were collected in clinical trials conducted at academic centers sponsored by the National Cancer Institute, or the NCI. These clinical trials tested the drug across a variety of cancers which are now known to produce this enzyme with a high frequency. The Licensee developed a proprietary, practical laboratory assay, or test, to identify patients whose cancers cannot produce this metabolic enzyme. In 2004, the Licensee was conducting Phase II trials of SDX-102 and are using their assay to select patients for these trials in difficult-to-treat cancers, including non-small cell lung cancer, or NSCLC, pancreatic and mesothelioma, none of which was previously studied by the NCI. The SDX-103 program involves analogs of the compound indanocine. Indanocine and indanocine analogs were synthesized and characterized at the University by the Licensee's founders. Indanocine displayed potent anti-proliferative activity when tested against a multitude of cancer cell lines at the NCI. These compounds differ from many clinically used drugs that block cell division in that they are active against multi-drug resistant cells and selectively kill non-dividing malignant cells. Anti-tumor activity of SDX-103 analogs has been observed in preliminary animal studies.
IPSCIO Record ID: 344526
Met-enkephalin, its application in in treating leukemia and other blood cancers;
Met-enkephalin, its application in preparation of human and animal vaccine;
A nasal spray formulation containing Met enkephalin;
Low dose naltrexone, combined with MENK, its application in preparation of anticancer drug;
Compound met-enkephalin as a drug for colon cancer and pancreatic cancer; and,
Naltrexone as well as analogues being anticancer drug;
and, any other intellectual property of Licensor relating to !he following Multiple, Cancer of the prostate. Lymphoproliferative syndrome. including such diseases as malignant lymphoma. chronic lymphocytic leukemia, Hodgkins lymphoma, and non-Hodgkins lymphoma and all reissues or modification. reexaminations. or other related Chinese. PTC or U.S. patent filings directed to the same subject matter.
Licensed Product means any protocols, methods, therapies, or patient information.
IPSCIO Record ID: 266765
The Wahl Patent Family shall mean U.S. Patents No. 6,251,362, and 6,022,521, including associated derivatives.
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are 'blood cancers' in the lymph nodes. They develop more frequently in older adults and in immunocompromised individuals. B-cell lymphomas include both Hodgkin's lymphomas and most non-Hodgkin lymphomas.
IPSCIO Record ID: 257483
This agreement includes a non-exclusive grant back to Licensor.
Compound shall mean RP5264 or one of the twoBackup Compounds.
Products shall mean a pharmaceutical preparation in any formulation that contains the Compound as an active ingredient.
RP-5264 is in phase I clinical trials for the oral treatment of B-cell lymphoma and mantle cell lymphoma.
The Primary Indications means B-cell Lymphomas and Chronic Lymphocytic Leukemia.